Evidence map›Paper›PMID 39976448›Full record

ArticlemSphere2025

Cross-laboratory replication of pseudomyxoma peritonei tumor microbiome reveals reproducible microbial signatures.

Victoria F Nieciecki, Faith C Blum, Ryan C Johnson, Traci L Testerman, Tom J McAvoy, Mary Caitlin King, Vadim Gushchin, Jeannette M Whitmire, Kenneth G Frey, Lindsay Glang and 5 more

Abstract read
In one paragraph

Article in mSphere, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Victoria F Nieciecki *Graduate Program in Cell & Molecular Biology, Colorado State University, Fort Collins, Colorado, USA.ORCID 0000-0002-1891-5909
Faith C Blum *Department of Microbiology and Immunology, Uniformed Services University, Bethesda, Maryland, USA.
Ryan C Johnson *Independent Researcher, Gaithersburg, Maryland, USA.
Traci L TestermanSchool of Medicine, University of South Carolina, Columbia, South Carolina, USA.
Tom J McAvoyDepartment of Chemical and Biomolecular Engineering, University of Maryland, College Park, Maryland, USA.
Mary Caitlin KingDepartment of Surgical Oncology, The Institute for Cancer Care at Mercy, Mercy Medical Center, Baltimore, Maryland, USA.
Vadim GushchinDepartment of Surgical Oncology, The Institute for Cancer Care at Mercy, Mercy Medical Center, Baltimore, Maryland, USA.
Jeannette M WhitmireDepartment of Microbiology and Immunology, Uniformed Services University, Bethesda, Maryland, USA.
Kenneth G FreyGenomics & Bioinformatics Department, Naval Medical Research Command, NMRC-Frederick, Fort Detrick, Maryland, USA.
Lindsay GlangGenomics & Bioinformatics Department, Naval Medical Research Command, NMRC-Frederick, Fort Detrick, Maryland, USA.
Dessiree Peña-GomezGenomics & Bioinformatics Department, Naval Medical Research Command, NMRC-Frederick, Fort Detrick, Maryland, USA.
Kimberly A Bishop-LillyGenomics & Bioinformatics Department, Naval Medical Research Command, NMRC-Frederick, Fort Detrick, Maryland, USA.ORCID 0000-0002-5744-8493
Armando SardiDepartment of Surgical Oncology, The Institute for Cancer Care at Mercy, Mercy Medical Center, Baltimore, Maryland, USA.
D Scott MerrellDepartment of Microbiology and Immunology, Uniformed Services University, Bethesda, Maryland, USA.ORCID 0000-0001-7095-5177
Jessica L MetcalfGraduate Program in Cell & Molecular Biology, Colorado State University, Fort Collins, Colorado, USA.ORCID 0000-0001-8374-8046

Funding

Predoctoral Training in Quantitative Cell & Molecular BiologyT32GM132057 · NIGMS · COLORADO STATE UNIVERSITY · PI Karen Marie Dobos, Brian Munsky · 2019 to 2026
$2.9M
HHS | National Institutes of Health (NIH) T32GM132057National Organization for Rare Disorders (NORD) 17003, 17005NIGMS NIH HHS T32 GM132057
6 · The paper itself

Abstract

Recent work has demonstrated that cancer-specific microbial communities often colonize tumor tissues. However, untangling low-biomass signals from environmental contamination makes this research technically challenging. We utilize pseudomyxoma peritonei (PMP), a cancer characterized by the spread of mucus-secreting cells throughout the peritoneal cavity, to develop a robust workflow for identifying reproducible tumor microbiomes. Typically originating from the rupture of an appendiceal tumor into the peritoneal cavity, metastasized tumors have been previously shown to harbor a core set of microbes. However, that work did not control for the potential contamination of these low microbial biomass samples. We expand upon these prior findings by characterizing the microbiome of 70 additional PMP tumors and six normal peritoneal control tissues along with appropriate laboratory controls. Additionally, DNA from a subset of 25 tissues was extracted and sequenced at an independent laboratory. We found evidence of reproducible microbial signatures between the replicates of six different PMP tumors that include a set of core taxa that may be introduced from surgical contamination, as well as patient-specific taxa that are also commonly implicated in colorectal cancer. In addition, preoperative chemotherapy treatment was found to reduce tumor microbiome diversity. Our findings demonstrate how independent sample replication can be a powerful approach to investigate low-biomass microbial communities associated with tumor tissues that will improve low microbial biomass research.IMPORTANCERecent work has demonstrated that microbial communities colonize over 30 different types of tumor tissues. The origin of these communities and their possible involvement in carcinogenesis or cancer treatment outcomes remains an unclear, yet important area of research. A current major challenge in characterizing low-biomass, tumor-associated microbiomes is the introduction of environmental contamination during collection, handling, DNA extraction, PCR, and sequencing. Here, we provide a framework for replicating low-biomass tumor microbiome samples to help identify tumors with robust microbial signals and low background contamination. Using this replication approach, we show that pseudomyxoma peritonei (PMP) tumors host reproducible microbial communities, including organisms that have previously been associated with colorectal cancer. Incorporating sample replication into future tumor microbiome studies is a promising approach that will help identify robust signals and increase reproducibility in the field.

Indexed as

BacteriaMicrobiotaPeritoneal NeoplasmsPseudomyxoma PeritoneiDNA, BacterialHumansReproducibility of ResultsRNA, Ribosomal, 16SDNA, BacterialRNA, Ribosomal, 16Samplicon sequencingcolorectal cancercontaminationPseudomyxoma Peritoneireproducibilitysource trackingtumor microbiome

Identifiers

PMID39976448
PMCPMC11934312

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.